Background: Europeans and American Indians were major genetic ancestry of Hispanics in the U.S. In those ancestral groups, it has markedly different incidence rates and outcomes in many types of cancers. Therefore, the genetic admixture may cause biased genetic association study with cancer susceptibility variants specifically in Hispanics. The incidence rate and genetic mutational pattern of liver cancer have been shown substantial disparity between Hispanic, Asian and non-Hispanic white populations. Currently, ancestry informative marker (AIM) panels have been widely utilized with up to a few hundred ancestry-informative single nucleotide polymorphisms (SNPs) to infer ancestry admixture. Notably, current available AIMs are predominantly located in intron and intergenic regions, while the whole exome sequencing (WES) protocols commonly used in translational research and clinical practice do not contain these markers, thus, the challenge to accurately determine a patient′s admixture proportion without subject to additional DNA testing. Methods: Here we designed a bioinformatics pipeline to obtain an AIM panel. The panel infers 3-way genetic admixture from three distinct continental populations (African (AFR), European (EUR), and East Asian (EAS)) constraint within evolutionary-conserved exome regions. Briefly, we extract ~1 million exonic SNPs from all individuals of three populations in the 1000 Genomes Project. Then, the SNPs were trimmed by their linkage disequilibrium (LD), restricted to biallelic variants only, and assembled as an AIM panel with the top ancestral informativeness statistics based on the In-statistic. The selected AIM panel was applied to training dataset and clinical dataset. Finally, The ancestral proportions of each individual was estimated by STRUCTURE. Results: In this study, the optimally selected AIM panel with 250 markers, or the UT-AIM250 panel, was performed with better accuracy as one of the published AIM panels when we tested with 3 ancestral populations (Accuracy: 0.995 ± 0.012 for AFR, 0.997 ± 0.007 for EUR, and 0.994 ± 0.012 for EAS). We demonstrated the utility of UT-AIM250 panel on the admixed American (AMR) of the 1000 Genomes Project and obtained similar results (AFR: 0.085 ± 0.098; EUR: 0.665 ± 0.182; and EAS 0.250 ± 0.205) to previously published AIM panels (Phillips-AIM34: AFR: 0.096 ± 0.127, EUR: 0.575 ± 0.29; and EAS: 0.330 ± 0.315; Wei-AIM278: AFR: 0.070 ± 0.096, EUR: 0.537 ± 0.267, and EAS: 0.393 ± 0.300) with no significant difference (Pearson correlation, P < 10-50, n = 347 samples). Subsequently, we applied UT-AIM250 panel to clinical datasets of self-reported Hispanic patients in South Texas with hepatocellular carcinoma (26 patients). Our estimated admixture proportions from adjacent non-cancer liver tissue data of Hispanics in South Texas is (AFR: 0.065 ± 0.043; EUR: 0.594 ± 0.150; and EAS: 0.341 ± 0.160), with smaller variation due to its unique Texan/Mexican American population in South Texas. Similar admixture proportion from the corresponding tumor tissue we also obtained. In addition, we estimated admixture proportions of entire TCGA-LIHC samples (376 patients) using UT-AIM250 panel. We demonstrated that our AIM panel estimate consistent admixture proportions from DNAs derived from tumor and normal tissues, and 2 possible incorrect reported race/ethnicity, and/or provide race/ethnicity determination if necessary. Conclusions: Taken together, we demonstrated the feasibility of using evolutionary-conserved exome regions to distinguish genetic ancestry descendants based on 3 continental-ancestry proportion, provided a robust and reliable control for sample collection or patient stratification for genetic analysis. R implementation of UT-AIM250 is available at https://github.com/chenlabgccri/UT-AIM250 .